share_log

万联证券4月24日发布研报称，给予华润三九（000999.SZ）买入评级。评级理由主要包括：1）CHC业务实现快速增长，处方药业务保持良性发展态势；2）昆药集团融合工作稳步推进；3）持续进行创新药、改良创新药、仿制药、经典名方等的开发或引进。（每日经济新闻）

Wanlian Securities released a research report on April 24 stating that it gave China Resources 39 (000999.SZ) a purchase rating. The main reasons for the rating include: 1) the CHC business has achieved rapid growth, and the prescription drug business has

Zhitong Finance ·  Apr 24 20:22
Wanlian Securities released a research report on April 24 stating that it gave China Resources 39 (000999.SZ) a purchase rating. The main reasons for the rating include: 1) the CHC business has achieved rapid growth, and the prescription drug business has maintained a positive development trend; 2) the integration work of the Kunyao Group is progressing steadily; 3) Continued development or introduction of innovative drugs, improved innovative drugs, generic drugs, classic famous recipes, etc. (Mainichi Keizai Shimbun)

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment